

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/752,619
				Filing Date	December 29, 2008
				First Named Inventor	Jesse Salb
				Art Unit	1616
				Examiner Name	Dameron Jones
Sheet	1	of	4	Attorney Docket Number	04646.P003D

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	5/29/03
-----------------------	---	--------------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complte if Known

Application Number	09/752,619
Filing Date	December 29, 2000
First Named Inventor	Jesse Salb
Group Art Unit	1616
Examiner Name	Dameron Jones
Attorney Docket Number	04646.P003D

RECEIVED
TECH CENTER 1600/2900
NOV 19 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
PQ		ANDERSON et al., "What does positron emission tomography offer oncology?". <i>Eur. J. Cancer</i> 36:2028-2035 (2000).	
		BENDER et al., "Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer", <i>Hybridoma</i> 18: 87-91 (1999).	
		BROCK et al., "Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas". <i>Br. J. Cancer</i> 82:608-615 (2000).	
		CONTI et al., "PET and [18F]-FDG in oncology: a clinical update", <i>Nuc. Med. Biol.</i> 23:717-735 (1996).	
		DEHDASHTI et al., "Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy", <i>Eur. J. Nucl. Med.</i> 26: 51-56 (1999).	
		FINDLAY et al., "Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil", <i>J. Clin. Oncol.</i> 14: 700-708 (1996).	
		FISCHMAN, "Positron Emission Tomography in the Clinical Evaluation of Metastatic Cancer", <i>J. Clin. Oncol.</i> 14: 691-696 (1996).	
		FISCHMAN, "The role of positron emission tomography in pharmacokinetic analysis", <i>Drug Metab. Rev.</i> 29: 923-956 (1997).	
		FOWLER et al., "PET and drug research and development". <i>J. Nucl. Med.</i> 40:1154-1163 (1999).	
		GERAN et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems", <i>Cancer Chemother. Rep.</i> 3: 51-61 (1972).	
PQ		GREEN et al., "Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose", <i>J. Nucl. Med.</i> 39: 729-734 (1998).	

Examiner Signature

Date Considered

11/29/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NOV 15 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	09/752,619
Filing Date	December 29, 2000
First Named Inventor	Jesse Salb
Group Art Unit	1616
Examiner Name	Dameron Jones
Attorney Docket Number	04646.P003D

TECH CENTER 1600/2900
NOV 19 2002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		HENDRIKSE et al., "Visualization of multidrug resistance in vivo". <i>Eur. J. Nucl. Med.</i> 26:283-293 (1999).
		HIETALA, "Ligand-receptor interactions as studied by PET: implications for drug development", <i>Ann. Med.</i> 31: 438-443 (1999).
		HOH et al., "PET in oncology: will it replace the other modalities?", <i>Semin. Nuc. Med.</i> 27:94-106 (1997).
		HOEY & SMITH , in Sovak ed., "Handbook of Experimental Pharmacology: Radiocontrast Agents", 73: 22-125, Springer-Verlag, NEW YORK (1984).
		JERUSALEM et al., "Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", <i>Blood</i> 94: 429-433 (1999).
		KNUUTI et al. "PET as a cardiovascular and metabolic research tool", <i>Ann. Med.</i> 31: 450-456 (1999).
		PRICE & JONES "Can Positron Emission Tomography (PET) be Used to Detect Subclinical Response to Cancer Therapy?", <i>Eur J Cancer</i> 31A: 1924-1927 (1995).
		ROMER et al., "Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose", <i>Blood</i> 91: 4464-4471 (1998).
		SCHELLING et al., "Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer". <i>J. Clin. Oncol.</i> 18:1689-1695 (2000).
		SCHULTE et al., "Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET". <i>J Nucl. Med.</i> 40: 1637-1643 (1999)
		SMITH et al., "Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy". <i>J. Clin. Oncol.</i> 18:1676-1688 (2000).

Examiner Signature

Date Considered

Sep 9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Examiner Signature		Date Considered 5/29/83	
-----------------------	---	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard S.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document.

¹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ²Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Substitute for Form 1449A/PTO (Modified) (use as many sheets as necessary)		Attorney Docket No.: 04646.P003D	Application Number: 09/752,619
 Page <u>2</u> of <u>2</u>		First Named Inventor: Jesse Salb	Filing Date: 12/29/2000
OTHER ART - NO PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation ²
		PCT International Search Report for PCT Int'l Appln No. US01/08612, mailed 16 August 2002 (9 pages).	TECH CENTER NOV 22 2002
		XU, YIMING et al. "Synthesis of Radioiodinated 1-Deoxy-Nojirimycin Derivatives: Novel Glucose Analogs," <u>Nuclear Medicine and Biology</u> , Vol. 26, No. 7, p. 833-839 (1999), Document No. XP-001037809.	RECEIVED 1600/2900
		MAGATA, YASUHIRO et al. "Development of a Novel Radioiodinated Glucose Derivative with Interaction to Hexokinase," <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , Vol. 31, No. 4, p. 317-328 (1992), Document No. XP-000675967.	NOV 22 2002
		LUTZ, T. et al. " ¹²³ I-Iodobenzoylglucosamines: Glucose Analogues for Heart Imaging," <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , Vol. 33, No. 4, p. 327-344 (1993), Document No. XP-008002378.	
Examiner Signature			Date Considered <u>12/29/03</u>

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for Form 1449A/PTO (Modified) (use as many sheets as necessary)		Attorney Docket No.: 04646.P003D	Application Number: 09/752,619	
 Page <u>1</u> of <u>1</u>		First Named Inventor: Jesse Salb Filing Date: <u>12/29/2000</u>		
OTHER ART - NO PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		Translation ²
		BECH, LARS; DIEMER, NILS HENRIK; and GJEDDE, ALBERT. "Metabolic effect of topical application of metrizamide to rat brain cortex." <u>Acta Neurol Scand.</u> , vol. 72, pages 427-431 (June 1985).		
		GJEDDE, ALBERT. "The blood-brain barrier is impermeable to metrizamide." <u>Acta Neurol. Scandinav.</u> vol. 66, pages 392-395 (1982).		
		SIGEL, PETER and PETTE, DIRK. "Intracellular localization of glycogenolytic and glycolytic enzymes in white and red rabbit skeletal muscle; a gel film method for coupled enzyme reactions in histochemistry." <u>The Journal of Histochemistry and Cytochemistry</u> , vol. 17, no. 4, pages 225-236 (September 1968).		
				

Examiner Signature		Date Considered	<u>5/29/03</u>
--------------------	---	-----------------	----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.